Fitbit’s latest earnings call was a mixed bag for the wearable giant. The company’s revenue and device sales were up; however, the average price of the devices was down. This has led to the company to lower its revenue guidance by $95 million.
It appears to be continuing to focus in on its health division, which is seeing an uptick in year-over-year revenue, and is on track to meet its $100...
In Dexcom’s latest earnings report, executives reported not only growing revenues and sales volume for the company, but a sense that the whole category of CGMs has arrived and is transforming diabetes care for the better, noting trends observed at the recent annual meeting of the American Diabetes Association.
“We have been on record for years telling that the future is ‘CGM First’ and we believe...
Following another rough quarter, NeuroMetrix has sought outside help in an effort to restructure its business and is pivoting away from a direct-to-consumer business model for its wearable pain relief platform, Quell.
“NeuroMetrix has good product lines and technology, and more broadly, the company has real value,” Dr. Shai Gozani, CEO and president of NeuroMetrix, told investors in a recent...
On yesterday’s Q1 earnings call, Fitbit CEO James Park spoke quite a bit about his product’s potential for a wider role in healthcare. He highlighted the device’s popularity among researchers, the recent Dana Farber study, and even the anecdote of the device being used to make a treatment decision about a patient’s atrial fibrillation. But he didn’t stop there.
“We are learning that lack of...
